Luitko sä ollenkaan tota linkkaamaasi juttua ollenkaan vai etkö ymmärrä englantia?
Edelleen tuolla lukee selvästi :
-Helmikuussa 2021 käynnistetty arviointi kolmannen rokotteen turvallisuudesta ja siihen otetaan jopa 144 osallistujaa jotka ollut jo ekassa vaiheessa mukana. Siis jopa 144 osallistujaa... vakuuttavaa.
-Pfizerin rokotteella edelleen vain EUA lupa.
-Raskaana olevilla 2 vaiheen testit aloitettu helmikuussa 2021
-Alle 12v testit aloitettu maaliskuussa 2021 (koska aikovat kyllä rokottaa lapset 11kk iästä alkaen kuten tuolla sanotaan)
ei ole kummoisesti testituloksia "additional group":lla , mut hei ei kai sillä väliä.
Ja kyllä , kliiniset testit tehty viime vuoden puolella ja siihen osallistunut eri ikä ryhmiä ja yli 40k koehenkiöä, mut samaan aikaan sanovat :
Nyt huhtikuussa julkaistaan tutkimustuloksia ja hyvä niin, että ei mitään pahempia sivareita ole löytynyt, mutta rokotetta tähän mennessä tykitetty jo ties kuinka helvetin monelle ja testejä vasta kursitaan kasaan.
Yleensä tutkimustulokset tulee reilusti ennenkuin aletaan jakamaan rokotetta muille kuin testiin osallistuville. Mikä siinä on niin vaikea ymmärtää?
Aivan absurdia ajatus, että aiemmin tuhlattiin huvikseen yli 10vuottakin ja käsittääkseni satoja miljoonia dollareita kehitykseen, kun sen kaiken olis voinut tehdä pikana alle vuodessa.
No toivottavasti on turvallinen rokote kaikille ryhmille.
Niin raskaana oleville ja lapsille sitä tutkitaan, voiko sitä käyttää.
Phase1 Pfizer;
RESULTS
A total of 195 participants underwent randomization
https://www.nejm.org/doi/full/10.1056/NEJMoa2027906
Vähemmän joka on täysin normaalia. Ja näiden jälkeen lapsia ja raskaana olevia. Ihan normaalia. Ekana vähemmän populaa ja kun turvallisuus tiedot lisääntyy niin voidaan koko kansaa loppujen lopuks. En ymmärrä mikä ongelma? Luottaisin viranomaisiin enemmän. Ja jos niistä tulis jotain juttua niitä ei päästettäis potilaille. 4 rokotetta on hylätty. Joko ei toimi tai ei ole turvallisia.
Phase 2 ja 3 yhdistetty;
On July 27, the companies announced the
launch of a Phase 2/3 trial with 30,000 volunteers. On Sept. 12, Pfizer and BioNTech
announced that they would seek to expand the trial to 44,000 participants.
Through the summer and into the fall, the world focused more and more of its attention on the Pfizer-BioNTech trial. In September, Dr. Albert Bourla, the chief executive of Pfizer,
said that as soon as October the Phase 3 trial would deliver enough results to show if the vaccine worked or not. President Trump touted their progress, hinting that a vaccine would be available before the election. But on Oct. 27, Dr. Bourla
announced that the volunteers in the trial had yet to experience enough cases of Covid-19 to determine if the vaccines work. Finally, on Nov. 9, Pfizer and BioNTech released their preliminary analysis of the first 94 cases.
Over the next month, Pfizer and BioNTech released more data on more cases. On Dec. 8 the FDA released
their independent analysis of the clinical trials. They determined that Comirnaty has an efficacy rate of 95 percent. While Comirnaty caused no serious side effects, it frequently caused short-lived fatigue, fever, and muscle aches.
These impressive results led rapidly to authorizations across the world. On Dec. 2, the United Kingdom gave
emergency authorization to Pfizer and BioNTech’s vaccine, followed by many more countries. On Dec. 31, the World Health Organization gave the vaccine an
Emergency Use Listing, which will speed up its authorization across the world. In Israel, which took the lead in mass vaccination, researchers found that the vaccine was
as effective in the real world as the trials had indicated. A study published by the Centers for Disease Control in March
found that the vaccine is 91.3% effective after the second dose.
As the trials progressed, Pfizer and BioNTech also scaled up factories to produce Comirnaty in huge amounts. They currently
expect to manufacture 2 billion doses worldwide by the end of 2021. The Trump administration
awarded a $1.9 billion contract in July for 100 million doses, but The New York Times reported in December that the administration
passed up the chance over the summer to secure another 100 million doses. Since then, the Trump and Biden administrations
reached agreements for a total of
300 million doses by the summer.
While Comirnaty has proven highly effective, it was initially a challenging vaccine to distribute because it had to be kept frozen at –94°F (–70°C). On Feb. 19, Pfizer and BioNTech
announced that they could keep the vaccine stable at -25°C to -15°C (-13°F to 5°F).
In January, scientists grew concerned about
the emergence of fast-spreading variants that might be able to evade antibodies. Tests on
a variant called P.1, first identified in Brazil, showed that Comirnaty
would likely work against it as well. However, researchers found that antibodies produced by Comirnaty are
somewhat less effective against another variant called
B.1.351, first identified in South Africa. On Feb. 26, the companies
announced a study to develop a B.1.351-specific booster.
In their initial trial, Pfizer and BioNTech did not include pregnant women among their participants. On Feb. 15 they
registered a trial specifically for pregnant women. The trial will determine whether the vaccine provides as much protection for them as for women who aren’t pregnant, and also gather information on its safety. Currently, the Centers for Disease Control
says pregnant women who become eligible may choose to get vaccinated, while pointing out the lack of data from trials.
Comirnaty is one of several vaccines being tested in an
Oxford study to gauge how well alternating doses promote immunity.
On March 31, Pfizer and BioNTech announced that their vaccine is
highly effective in adolescents 12 to 15 years old.
Tämän lisäks tutkittu 805000 ruotsissa ja 1,2 miljoonaa israelissa.
https://www.nejm.org/doi/full/10.1056/NEJMc2101951
Mm. hylätyt rokotteet on
Imperial College London
merc themis
merc iavi
University of Queensland
Eli osotuksena että toimii valvonta.
Phase 3ssa on 23 eri rokotetta koronaan tulossa joita ei ole päästetty markkinoille, edes ''emercency use'' periaatteella.
Ps moderna rokote kehitettiin muuten 2ssa päivässä.

turvallisuus jutuissa meni ihan vitusti.
yks pääjehuista oli hän.
View: https://www.instagram.com/p/CL_AZYxD2tZ/